On Thursday, Shares of Exelon Corporation (NYSE:EXC), lost -1.24% to $28.74.
As temperatures start to drop, PECO has accomplished more than a dozen projects to keep the lights on and natural gas flowing for customers all winter long.
Each year, PECO invests nearly $100 million in the company’s natural gas system to provide safe and reliable service for customers. This work comprises equipment inspections, repairs and replacements, and preventive maintenance on the company’s natural gas transmission and distribution system.
This year PECO installed more than 6,600 feet of underground natural gas main to meet the growing needs of customers. The company also accomplished 80 projects to replace more than 95,000 feet of existing natural gas line with new plastic pipe, which enhances safety, is more durable and improves service. PECO also has secured natural gas supply and accomplished filling storage facilities to serve more than 508,000 natural gas customers this heating season.
The company also has inspected more than 10,000 miles of aerial electric lines and more than 2,100 manholes to examine and make any needed repairs to underground electrical equipment. PECO also has accomplished eight electrical enhancement projects to meet raised customer demand during the winter. This seasonal readiness work is a part of $500 million invested each year in the company’s electric system.
Exelon Corporation, a utility services holding company, engages in the energy generation and delivery businesses in the United States. It owns electric generating facilities, such as nuclear, fossil, and hydroelectric generation facilities, in addition to wind and solar photovoltaic facilities.
Shares of Alere Inc (NYSE:ALR), declined -9.34% to $42.43, during its last trading session.
Alere, declared its financial results for the quarter ended September 30, 2015. Net revenue for the third quarter of 2015 was $602.0 million, a 7.3 percent decrease contrast to $649.2 million in the third quarter of 2014, or a 1.7 percent decrease in organic growth, which is on a constant currency basis, not taking into account impacts of acquisitions and divestitures. Net income from ongoing operations available to common stockholders was $0.2 million, or $0.00 per diluted share, in the third quarter of 2015. On a non-GAAP basis, the Company stated non-GAAP adjusted net income from ongoing operations available to common stockholders of $48.3 million, or $0.54 per diluted share, in the third quarter of 2015.
Third Quarter Highlights
- Alere receives FDA CLIA Waiver for Alere™ i Strep A Rapid Molecular Test
- Alere Agrees to Sell BBI Group and Acquires US Diagnostics
- Geoffrey S. Ginsburg Joins Alere Board
Third Quarter 2015 Results
Third quarter 2015 net revenue of $602.0 million declined by $47.2 million from $649.2 million, or 7.3 percent, contrast to the preceding year period, primarily due to a $33.0 million negative impact from foreign currency exchange; a $12.6 million decrease in pain administration; and a $7.7 million decrease in global sales of INRatio. In addition, BBI revenue and contract manufacturing revenue associated with our consumer joint venture declined by $8.7 million and CD4 and malaria sales in Africa reduced by $8.0 million during the third quarter. Growth areas comprised: patient self-testing, Afinion and epoc in Cardiometabolic Disease; dengue in Infectious Disease; and employer services and reagents in Toxicology. Global influenza sales were $19.6 million in the third quarter of 2015, a 15.9 percent improvement over the preceding year period, counting about $4.9 million in Alere i sales.
Gross profit in the third quarter of 2015 was $275.0 million, with 45.7 percent gross margin, contrast to $301.6 million in the third quarter of 2014, with 46.5 percent gross margin. Non-GAAP adjusted gross profit in the third quarter of 2015 was $292.5 million, with 48.5 percent non-GAAP adjusted gross margin, contrast to $323.6 million in the third quarter of 2014, with 49.8 percent non-GAAP adjusted gross margin. Non-GAAP adjusted gross profit excludes amortization of acquisition-related intangibles, restructuring charges, and stock-based compensation.
Alere Inc. provides point-of-care diagnostics and services for infectious disease, cardiometabolic disease, and toxicology in the United States and internationally. The company operates through Professional Diagnostics and Consumer Diagnostics segments. Its cardiometabolic products and services comprise tests to assist in the diagnosis and administration of various cardiometabolic factors and conditions, counting cardiac markers, glucose and HbA1C, cholesterol levels, blood gases, and home monitoring for VAD and oral anticoagulation.
Finally, Shares of Lennar Corporation (NYSE:LEN), ended its last trade with -1.82% loss, and closed at $49.07.
Lennar Corporation, declared that its Rialto Capital partner has accomplished the first closing of commitments from the entities that comprise its third opportunistic real estate investment fund with initial equity commitments of $510 million (counting $100 million committed by Rialto). The Fund’s objective during its investment period is to invest primarily in real estate debt and properties that fit within the Fund’s investment parameters.
This declaration does not constitute an offer to sell or a solicitation of an offer to buy securities in the United States. Interests in the Fund have not been registered under the Securities Act of 1933, as amended, or any U.S. state securities law, and may not be offered or sold in the United States absent registration or an applicable exemption from registration requirements.
Lennar Corporation, together with its auxiliaries, engages in the homebuilding activities in the United States. The company operates through Homebuilding East, Homebuilding Central, Homebuilding West, Homebuilding Southeast Florida, Homebuilding Houston, Financial Services, Rialto, and Lennar Multifamily segments.